Human immunoglobulin preparations for intravenous or subcutaneous administration are
the cornerstone of treatment in patients with primary immunodeficiency diseases affecting …

Chronic spontaneous urticaria (CSU) is a mast cell–driven skin disease characterized by the
recurrence of transient wheals, angioedema, or both for more than 6 weeks. Autoimmunity is …

This review presents evidence that the skin mast cell, in particular the MCTC subtype, is the
primary effector cell in urticaria. Mast cells are located in the upper dermis, the ideal situation …

This update on chronic urticaria (CU) focuses on the prevalence and pathogenesis of
chronic spontaneous urticaria (CSU), the expanding spectrum of patient-reported outcome …

Background The efficacy of omalizumab (anti-IgE) and increased IgE levels in patients with
chronic spontaneous urticaria (CSU) suggest autoallergic mechanisms. Objective We …

The monoclonal anti‐immunoglobulin E (IgE) antibody, omalizumab, was the first drug
approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who …

Recognition of non-self molecular patterns by pattern recognition receptors is a cornerstone
of innate immunity. Toll-like receptors (TLRs) exert a key role in recognizing pathogen …

▪ Abstract The high affinity receptor for immunoglobulin E (designated FcϵRI) is the member
of the antigen (Ag) receptor superfamily responsible for linking pathogen-or allergen-specific …

Urticaria is a common, mast cell-driven disease presenting with wheals or angioedema or
both. In the last years, urticaria has increasingly attracted notice to clinicians and …

Background A subgroup of patients with chronic spontaneous urticaria (CU) exhibits IgE
antibodies directed against autoantigens, such as thyroperoxidase (TPO). We conducted …